BioSpace News Archive

Sesen Bio announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating results for the first quarter ended March 31, 2019 and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial of Vicinium® for patients with high-risk non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin.

OncoSec Medical Incorporated announced that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the ThinkEquity Conference 2019 on Thursday, May 2, 2019, at 11:30 a.m. ET in New York, NY.

Heritage Provider Network to Unveil This Year’s Winners at Celebratory Luncheon Honoring Healthcare Trailblazers in New York Metropolitan Area

Highlights include oral presentation on long-term efficacy and safety of pitolisant and key data analyses from pivotal trials

TraceLink Inc., the world’s largest integrated digital supply network providing real-time information sharing for better patient outcomes, announced the speaker lineup and newly introduced Advisory Board for FutureLink Barcelona.

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL®i (etanercept).

Motus GI Holdings, Inc. announced that full clinical results from the Company’s REDUCE study evaluating the Pure-Vu® System will be presented at Digestive Disease Week® 2019, being held May 18 - 21, 2019 in San Diego, CA.

Additional investments to energize existing market growth and accelerate new product development

The investment was made by Signet Healthcare Partners (“Signet”), a New York based growth equity firm specializing in healthcare investments.

Blood Centers of America includes over 50 members providing nearly 40% of the U.S. blood supply